** U.S.-listed shares of Australia-based Mesoblast MSB.AX rise 44.2% to $17.67 premarket
** The U.S. Food and Drug Administration late on Wednesday approved co's cell therapy for treating graft-versus-host disease (GVHD)
** The therapy, branded as Ryoncil, is approved to treat pediatric patients aged two months and older whose GVHD symptoms have not responded to standard steroid therapy
** GVHD is a complication that might occur after a cell transplant, where the donated stem cells attack the recipient's cells, mistaking them for an unfamiliar threat
** Up to last close, stock rose ~457% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。